Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Open access

Abstract

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b02052

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Jarvis, 2016, Have drug hunters finally cracked KRAS?, Chem. Eng. News, 94, 28

Cited by

See all 671

Metadata

Authors
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., Chiang, H., Chicarelli, M. J., Cook, A. W., Gaudino, J. J., Hallin, J., Hanson, L., Hartley, D. P., Hicken, E. J., Hingorani, G. P., Hinklin, R. J., Mejia, M. J., Olson, P., Otten, J. N., Rhodes, S. P., Rodriguez, M. E., Savechenkov, P., Smith, D. J., Sudhakar, N., Sullivan, F. X., Tang, T. P., Vigers, G. P., Wollenberg, L., Christensen, J. G., & Marx, M. A.
Affiliations
  • Array BioPharma (United States) (US)
  • Mirati Therapeutics (United States) (US)
Corresponding author
  • Fell, Jay B.
  • Marx, Matthew A.
Venue
Journal of Medicinal Chemistry
Published
2020-04-06
Volume
63
Issue
13
Pages
6679-6693
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3014882016
Cited by
653
References
31
Citations by year
2026: 117 · 2025: 109 · 2024: 147 · 2023: 114 · 2022: 87 · 2021: 51 · 2020: 28
FWCI
24.01
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, other-oa)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
adagrasib, KRAS G12C, covalent inhibitors, switch-II pocket, structure-based drug design, ADME profiling, metabolic liability, cancer therapy
MeSH terms
Animals, Antineoplastic Agents, Drug Screening Assays, Antitumor, Enzyme Inhibitors, Humans, Models, Molecular, Mutation, Drug Design, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b02052
The paper
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., Chiang, H., Chicarelli, M. J., Cook, A. W., Gaudino, J. J., Hallin, J., Hanson, L., Hartley, D. P., Hicken, E. J., Hingorani, G. P., . . . Marx, M. A. (2020). Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b02052

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.